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Objective. To explore fecal calprotectin levels in pediatric ulcerative colitis (UC) in relation with the validated clinical activity index
PUCAI.Methods.This study included all 37 children (median age 14 years) with UCwho had calprotectin measured (PhiCal ELISA
Test) by the time of PUCAI assessment at the Children’s Hospital of Helsinki in a total of 62 visits. Calprotectin values <100𝜇g/g
of stool were considered as normal. The best cut-off value of each measure to predict 3-month clinical outcome was derived by
maximizing sensitivity and specificity. Results. In clinically active disease (PUCAI ≥ 10), calprotectin was elevated in 29/32 patients
(91% sensitivity). When in clinical remission, 26% (8/30) of the children had normal calprotectin but 7 (23%) had an exceedingly
high level (>1000𝜇g/g).The best cut-off value for calprotectin for predicting poor outcomewas 800𝜇g/g (sensitivity 73%, specificity
72%; area under the ROC curve being 0.71 (95%CI 0.57–0.85)) and for the PUCAI best cut-off values>10 (sensitivity 62%, specificity
64%; area under the ROC curve 0.714 (95%CI 0.58–0.85)). Conclusion. The clinical relevance of somewhat elevated calprotectin
during clinical remission in pediatricUC is not known and, until further evidence accumulates, does not indicate therapy escalation.
1. Introduction
Neutrophil-derived markers, such as fecal calprotectin or
lactoferrin, have proven to correlate well with mucosal
inflammation of ulcerative colitis (UC) at a rho range of
0.6–0.8 [1–4]. Fecal level of thesemarkers reflects themucosal
influx of inflammatory cells in the gut.When the level of these
markers is low, the presence of active inflammation in the
colon is unlikely [3, 5–8]. The probability of 1-year remission
in UC children with normal calprotectin may be as high as
75% [9]. On the other hand, in UC (and unlike in Crohn’s dis-
ease), clinical judgment of symptoms also correlates well with
endoscopic appearance, at a range of rho 0.7–0.8 [10], and
clinical assessment also predicts well clinical outcomes in
both adult [11] and pediatric severe UC [12]. Recently, we
showed that calprotectin levels rarely decline completely dur-
ing therapy with glucocorticoids or TNF-𝛼-antagonist agents
suggesting ongoing inflammation in the majority [13, 14].
The PUCAI is the validated pediatric ulcerative colitis
activity index showing good correlation with endoscopic
disease activity [15–17]. The index is based on item scores
reflecting the clinical situation within the last two days and
may thus be used in the acute setting [15]. In acute severe
colitis, PUCAI reflects therapeutic response better than cal-
protectin, the levels of which do not change as rapidly along
improvement as the PUCAI scores [18, 19]. There are, how-
ever, limited data on the performance of fecal markers related
to simple clinical assessment of pediatric UC in clinical
practice. We aimed to explore calprotectin levels in relation
to clinical disease activity assessed with the validated activity
index PUCAI in pediatric UC.
2. Subjects and Methods
This retrospective study included all children with UC who
had calprotectin measured and clinical data recorded for
the assessment of the PUCAI at the Children’s Hospital of
Helsinki from December 2005 to January 2012, most samples
being from the three recent years. Diagnosis of UCwas based
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on typical clinical presentation as well as upper and lower
endoscopy [20].
Clinical disease activity was scored using the PUCAI
consisted that of six clinical items scored from 0 to 85 points
(abdominal pain 0–10; rectal bleeding 0–30; stool consistency
0–10; number of stools per 24 hours (0–15); nocturnal stools
(0–10), and activity level (0–10)). Cut-off scores for remission
(PUCAI < 10 points), mild (10–34), moderate (35–64)) and
severe (≥65) disease activity have been validated on three
different cohorts with sensitivity and specificity of >90%
[10, 15, 16].
Three-month clinical outcome was assessed using a
physicians global assessment (PGA) from 0 (remission) to 3
(severe disease). Good outcome was defined as no need
to change maintenance medication, successful weaning of
steroids when applicable, and disease activity of nomore than
1 according to PGA.
Children provided a stool sample within two days of the
time of PUCAI assessment. The samples in children under-
going endoscopy were taken prior to bowel cleansing [21].
Fecal calprotectin was measured using the PhiCal ELISA Test
(Nova Tec Immunodiagnostica, Dietzenbach, GmBH, Ger-
many). Calprotectin value <100 𝜇g/g of stool was considered
as normal whereas values >1000 𝜇g/g were considered as
exceedingly high [9, 13, 14].
2.1. Ethics. The patients involved in this study participated in
a study on pediatric inflammatory bowel disease approved
by the Ethics Committee of the Helsinki University Central
Hospital. The patients/their guardians signed an informed
consent form when entering the study.
2.2. Statistical Analyses. Data are presented as means
(±standard deviation) or medians (interquartile range) as
appropriate for the distribution normality. Correlations
between individual parameters were sought using Spearman
correlation. To compare the predictive utility of the PUCAI
as compared with calprotectin, area under the receiver
operating characteristics (ROC) curve (±95% CI) was used.
The best cut-off values of each measure to predict 3-month
clinical outcome were derived by maximizing sensitivity and
specificity. All analyses were performed using SPSS V16.
3. Results
A total of 62 visits were included from 37 different children
with fecal calprotectin values available by the time of the
assessment of the PUCAI ( 18 (49%) males, median age 14.3
years (IQR 13.0–15.8, 33 (89%) with extensive disease and
the others with left-sided disease; Table 1). Fourteen (38%)
children were at disease onset and the others with median
disease duration of 1.5 (IQR 0.7–3.0) years. Sixteen of the
visits were during clinical remission (judged by PGA), 16
(26%) during mild disease activity, 12 (19%) during moderate
disease activity, and 18 (29%) during severe disease activity.
Median number of samples per patient was 1 (IQR: 1-2, range
1–5).
Table 1: Background data of the 37 pediatric patients with ulcerative
colitis.
Age (years) 14 (median, range 4.5–17)
Gender Male 𝑛 = 18
Disease duration (years) 1.5 (median, range 0–5)
Disease extension Pancolitis 𝑛 = 33
Left-sided colitis 𝑛 = 4
Medication 5-ASA 𝑛 = 13
5-ASA and/or azathioprine 𝑛 = 5
Infliximab 𝑛 = 8
Glucocorticoids 𝑛 = 11
None 𝑛 = 11
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Figure 1:The Spearman correlation of the pediatric ulcerative activ-
ity index (PUCAI) and fecal calprotectin in pediatric patients with
ulcerative colitis undergoing diagnostic endoscopy.
In the total sample set, the correlation of calprotectin and
the PUCAI was good (𝑟 = 0.53, 𝑃 < 0.001, 𝑛 = 62). The
correlation between PUCAI and calprotectin among the 14
children at diagnosis (all with clinically active disease) was
higher (𝑟 = 0.67, 𝑃 = 0.009; Figure 1).
The best calprotectin cutoff to identify the 30/62 visits
in clinical remission was <800𝜇g/g (sensitivity 73% and
specificity 72%; area under the ROC curve of 0.76 (95% CI
0.63–0.88); Figure 2). The values were not different when
considering only one observation per patient to avoid possi-
ble repeated measures bias (the first visit per patient; 𝑛 = 37)
with an area under the ROC curve of 0.71 (0.53–0.89) and
similar cut-off value.
Calprotectin was exceedingly high in all 13 samples
collected during a severe attack (i.e., PUCAI ≥ 65) (median
2179 𝜇g/g range 1190–9504 (IQR 1682–5310)). All those with
PUCAI scores reflecting moderate-severe disease (40–85)
had elevated calprotectin values. Inmild-to-moderate disease
(PUCAI 10–64, 𝑛 = 19) calprotectin was elevated in all except
two patients (median 829𝜇g/g, range 7–7287 (IQR 416–
1599)). Calprotectin was completely normal in 8 of 30 assess-
ments performed during clinical remission (26%). In seven
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Figure 2:The relation of the pediatric ulcerative activity index (PUCAI) and fecal calprotectin in pediatric patients with ulcerative colitis.The
arrow shows the best fecal calprotectin cutoff (by maximizing sensitivity and specificity) to identify patients in clinical remission according
the PUCAI.
(23%), calprotectin level was exceedingly high (>1000 𝜇g/g).
In four of these, the assessments were done on the day of
maintenance infusion of infliximab, in two cases steroids had
been tapered within one-to-two weeks earlier and, one was
on only 5-ASA. Three of these seven (two on infliximab, one
in whom steroids were tapered off) remained in sustained-
steroid-free clinical remission 3-months after the sample date,
despite the very high calprotectin level.
The PUCAI performed just as well as calprotectin in
predicting 3-month clinical outcome (poor versus good
outcome), area under the ROC curve being 0.71 (95% CI
0.57–0.85) versus 0.714 (95% CI 0.58–0.85), respectively. The
best cutoff for calprotectin for predicting poor outcome was
800𝜇g/g (sensitivity 73%, specificity 72%) and for the PUCAI
best cut-off >10 (sensitivity 62%, specificity 64%).
Of the 30 assessments in clinical remission, 20 (66%)
remained in steroid-free clinical remission for the forthcom-
ing three months. All 10 assessments of both clinical remis-
sion or mild clinical disease (i.e., PUCAI < 35), and normal
calprotectin <100, remained in steroid-free remission in 3
months. The calprotectin values and outcome of the patients
in remission or having mild-to-moderate disease activity
according to the PUCAI during the following three months
ara shown in Table 2.
4. Discussion
The use of calprotectin as a surrogate marker for intestinal
inflammation is emerging. However, the data on calprotectin
related to clinical disease activity in children with UC are
sparse. We show good correlation between the PUCAI and
fecal calprotectin. In the clinically severe disease (PUCAI >
65), calprotectin was exceedingly high (>1000 𝜇g/g) in all
cases and did not bring any additional information to clinical
assessment. It is worthwhile noting that the PUCAI is much
more responsive to a rapid change than calprotectin in severe
disease; that is, the PUCAI shows a sharp decrease within
only a few days of starting effective medication [18] reflecting
the well-known notion thatmucosal healing lags after clinical
remission. On the other hand, some of those in clinical
remission according to PUCAI still had elevated calprotectin
levels, but in the majority the levels were only moderately
elevated. Our data suggests, however, that closer monitoring
should be offered to the patients in clinical remission but with
exceedingly high calprotectin level since many of them may
show deteriorationwithin the forthcomingweeks. It may also
suggest that the current therapies are unable to induce com-
plete attenuation of mucosal inflammation in a large propor-
tion of the pediatric patients. Recently, we showed that only
one-third of 41 children with UC had normal calprotectin
levels while 13% had exceedingly high levels despite all being
in longstanding clinical remission defined using the PGA
(i.e., 80% with at least 6-month duration followup) [9].
Although mucosal healing has been shown in adults, to
predict favourable clinical outcome in UC [11, 22, 23] is yet
to be proven that this is superior to clinical assessment of
remission. Indeed, in the combined ACT cohorts (466 adults
with UC treated with either infliximab or placebo) endo-
scopic healing after 8 weeks of therapy predicted 1-year
colectomy overall but not among the subset of patients with
clinical remission [22]. Moreover, clinical judgment of res-
ponse to steroid treatment in acute severeUChas been shown
to predict long-term, clinically important, outcomes, both in
adults [11] and in children [12, 24], irrespective of endoscopic
healing. Similarly here, we could not find any major differ-
ence between clinical (PUCAI) and endoscopic (calprotectin)
assessment of disease activity with regards to predicting
3-month steroid free remission although the sensitivity
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Table 2: Three-month outcome of pediatric patients with mild-to-
moderate ulcerative colitis according to the clinical disease activity
index PUCAI and fecal calprotectin at baseline. The outcome was
determined according to physicians global assessment.
No.
Disease activity
according to the PUCAI
(total score)
Calprotectin
𝜇g/g of stool
Outcome within 3
months
1 Remission (<10) 14 Remission
2 14 Remission
3 16 Remission∗
4 30 Remission
5 45 Remission
6 69 Remission
7 69 Remission
8 90 Remission
9 131 Remission
10 155 Flare (within twomonths)
11 189 Flare (whentapering corticoid)
12 333 Remission∗
13 345 Flare
14 372 Remission
15 411 Remission
16 441 Remission
17 521 Remission
18 532 Flare (whentapering corticoid)
19 581 Remission
20 628 Remission
21 663 Flare (within amonth)
22 796 Remission
23 902 Flare∗
24 1052 Remission∗
25 1173 Flare∗
26 1233 Remission
27 1976 Flare (whentapering corticoid)
28 2295 Flare∗
29 4518 Flare (within twoweeks)
30 9625 Remission
31 Mild-to-moderatedisease (10–64) 7 Remission
32 55 Remission
33 87 Remission
34 327 Flare (whentapering corticoid)
35 416 Remission
Table 2: Continued.
No.
Disease activity
according to the PUCAI
(total score)
Calprotectin
𝜇g/g of stool
Outcome within 3
months
36 611 Lost from followup
37 653 Flare
38 751 Flare
39 766 Flare
40 829 Flare (ongoing)
41 856 Remission
42 Mild-to-moderatedisease (10–34) 1067 Flare
43 1110 Remission
44 1127 Remission
45 1599 Flare (when taperingcorticoid)
46 1667 Flare (within twoweeks)
47 1911 Flare (ongoing)
48 2604 Flare
49 7287 Flare (when taperingcorticoid)
∗Sample taken on the day of infliximab administration.
and specificity of calprotectin were somewhat higher than
the PUCAI.This should be interpreted with caution given the
small sample size, the retrospective design, and the relatively
short follow-up duration.
Notably, it remains an unanswered question whether
immunosuppressive therapy should be escalated during clin-
ical remission solely based on the presence of elevated calpro-
tectin.The question is not merely if calprotectin levels during
remission are independently predictive, but if the predictive
power is large enough to justify the associated adverse events.
In other words, how many children in remission will be
required to step up from 5-ASA to thiopurines or even anti-
TNF in order to obtain one favourable outcome (i.e., number
needed to treat). Currently, this cannot be recommended
until evidence is available to show that this aggressive
approach indeed leads to better outcomes.
Furthermore, the target level of fecal surrogate markers
to define acceptable therapeutic response is not known. In a
previous study, 89% of 25 young patients with Crohn’s disease
in clinical remission remained in remission for nine months
if their fecal calprotectin level was lower than 400𝜇g/g [25].
Here, the best cutoff for calprotectin for predicting 3-month
poor outcome was as high as >800𝜇g/g and for the PUCAI
scores ≥10 (which is the PUCAI definition for active disease)
with no major difference in sensitivity and specificity.
In conclusion, in pediatric UC, clinical disease activity
assessed with the validated index PUCAI shows good corre-
lation with the levels of calprotectin. At present, the clinical
relevance of elevated calprotectin level when in sustained
clinical remission is not known and, until known otherwise,
does not indicate escalating therapy based on this isolated
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finding only. However, it may indicate closer monitoring,
especially in those with values >800𝜇g/g.
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